Search company, investor...

Predict your next investment

Angel Investor (Group)
kansaswbc.com/womenscapitalconnection/tabid/1221/default.aspx

See what CB Insights has to offer

Investments

1

Portfolio Exits

1

About Women's Capital Connection

Headquarters Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Women's Capital Connection Investments

1 Investments

Women's Capital Connection has made 1 investments. Their latest investment was in Aratana Therapeutics as part of their Series B on December 12, 2011.

CBI Logo

Women's Capital Connection Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/7/2011

Series B

Aratana Therapeutics

$15M

Yes

2

Date

12/7/2011

Round

Series B

Company

Aratana Therapeutics

Amount

$15M

New?

Yes

Co-Investors

Sources

2

Women's Capital Connection Portfolio Exits

1 Portfolio Exit

Women's Capital Connection has 1 portfolio exit. Their latest portfolio exit was Aratana Therapeutics on June 27, 2013.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/27/2013

IPO

$99M

Public

1

Date

6/27/2013

Exit

IPO

Companies

Valuation

$99M

Acquirer

Public

Sources

1

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.